Application of Onalspib as ADV7 virus inhibitor
Onalespib is repurposed to address the lack of effective ADV7 antiviral drugs by inhibiting virus replication and enhancing cell survival, offering a promising therapeutic solution for ADV7 infections.
Patent Information
- Application Number
- CN202410992175.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a lack of effective antiviral drugs with strong specificity and minimal side effects for Human adenovirus type 7 (ADV7) infections, particularly in children, where current treatments primarily rely on symptomatic care.
Onalespib (AT13387) is repurposed as an inhibitor of ADV7 virus, demonstrating significant anti-viral activity by inhibiting cytopathic effects, enhancing cell survival, and reducing progeny virus production.
Onalespib effectively inhibits ADV7 virus replication and proliferation, increasing cell survival rates and reducing virus production, indicating its potential as a specific therapeutic drug for ADV7 infections.
Smart Images

Figure CN119055652A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antiviral drugs and relates to the use of Onalespib in the preparation of anti-ADV7 virus drugs. Background Art
[0002] Human adenovirus type 7 (ADV7) is a widely distributed non-enveloped double-stranded DNA virus with a diameter of 90-100nm. The capsid is dihedral and its replication does not depend on the division of host cells. Human adenovirus (ADV) infection is very common and can cause various diseases in the human body, mainly respiratory tract infections. There are three main types of adenoviruses associated with respiratory diseases, namely ADV-3, ADV-5 and ADV-7. It is known that adenoviruses have a small risk factor for causing serious diseases. Commonly, it can cause acute respiratory fever, but it has a great impact on children. In severe cases, it can cause pneumonia in children. ADV7 has been confirmed to be an important cause of pneumonia in children. ADV7 can cause severe or fatal respiratory tract infections in children under 7 years old, and it is easy to cause outbreaks and endanger the health of infants and young children. At present, there is a lack of drugs with strong specificity and few side effects for ADV7 infection in clinical practice. At present, symptomatic treatment is mainly adopted. Therefore, it is imperative to develop specific drugs against ADV-7 infection.
[0003] Onalespib (AT13387) is a synthetic, orally bioavailable, small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antitumor activity. 50 is 18nM. The Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival, and has long-lasting anti-tumor activity. AT13387 inhibits multiple kinases. However, AT13387 has no obvious inhibitory effect on experimental kinases when the concentration is below 30μM. AT13387 effectively inhibits the proliferation and survival of multiple tumor cell lines (such as the MES-SA cell line). The Kd of AT13387 binding in vivo is 0.7nM: the tolerated dose of AT13387 twice a week or once a week is 70mg / kg. In all cases except one, the weight loss of mice did not exceed 20% before recovery, and the weight loss was highest after the second dose. AT13387 acts on a group of 30 tumor cell lines, effectively inhibiting cell proliferation, GI 50 The value is 13-260nM. AT13387 inhibits the proliferation of non-tumorigenic prostate epithelial cell line PNT2. However, there are few reports on the use of AT13387 for antiviral therapy.
[0004] We evaluated the inhibitory activity of AT13387 against ADV7 virus. Summary of the invention
[0005] The purpose of the present invention is to provide Onalespib as an effective inhibitor of ADV7 virus in view of the above situation.
[0006] Onalespib (C 24 H 31 N3O3) has the following chemical structure:
[0007]
[0008] The object of the present invention is achieved by testing the activity of Onalespib using a standard viral activity test method.
[0009] Through a large number of biological experiments, the applicant found that Onalespib has anti-ADV7 virus activity. Specifically, it can inhibit the cytopathic effect caused by the ADV7 virus, enhance the survival rate of infected cells, inhibit the replication and proliferation of the ADV7 virus in cells, and reduce the production of progeny viruses. This shows that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 It is the effect of Onalespib on the survival rate of Hela cells acted with ADV7.
[0011] Figure 2 It is the inhibitory effect of Onalespib on CPE of Hela cells caused by ADV7.
[0012] Figure 3 It is the inhibitory effect of Onalespib on the production of ADV7 progeny viruses. DETAILED DESCRIPTION
[0013] Onalespib (AT13387) used in the present invention was purchased from a reagent company.
[0014] The present invention relates to the application of Onalespib (AT13387) in the preparation of anti-ADV7 virus drugs.
[0015] The application refers to adding pharmaceutically acceptable excipients and carriers to Onalespib (AT13387) to prepare an anti-ADV7 virus preparation.
[0016] The preparation is granules, tablets, pills, capsules, injections or dispersions.
[0017] Onalespib (AT13387) of the present invention has the following chemical structural formula:
[0018]
[0019] The application of AT13387 in the present invention as an anti-ADV7 virus has shown that AT13387 has a significant anti-ADV7 virus effect, which indicates that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects.
[0020] The applicant has conducted an anti-ADV7 activity research experiment on the above compounds, and the experimental results are as follows: In the following, unless otherwise specified, the materials and operating methods used in the present invention are well known in the art.
[0021] 1. Test content:
[0022] Analysis of compound anti-ADV7 activity: The present invention combines cytopathic effect analysis and MTT cell viability assay to evaluate the anti-ADV7 activity of AT13387.
[0023] 2. Test methods:
[0024] 2.1.1 Toxicity of compounds to host Hela cells
[0025] Hele cells were plated on 96-well plates and cultured in a 37°C, 5% CO2 incubator until the cells grew to a monolayer. The cell culture medium was discarded and cell maintenance medium containing different concentrations of the test compound was added to continue culturing. After 48 hours, the cytotoxicity was observed under a microscope and recorded. The cell survival rate was determined by the MTT method. SPSS11.5 software was used to calculate the median cytotoxic concentration (CC) of the drug for cells. 50 ). Cell survival rate = (mean OD of drug group 492 Value / average OD of cell control group 492 value)×100%.
[0026] 2.1.2 Inhibitory activity of compounds against ADV7
[0027] Hela cells were plated on a 96-well plate and cultured in a 37°C, 5% CO2 incubator until the monolayer was fully grown. The culture medium was discarded, and the cells were infected with 100TCID50 ADV7 virus solution for 1.5 hours. Different concentrations of test compounds (ribavirin as a positive control drug) were added to incubate the cells. After continuing to culture for about 48 hours, when about 90% CPE lesions appeared in the virus control wells, the cytopathic effect (CPE) was observed under a microscope. The observation and recording method of CPE: no cytopathic effect was recorded as -, 25% or less cytopathic effect was recorded as +, 25%-50% cytopathic effect was recorded as ++, 50%-75% cytopathic effect was recorded as +++, and 75% or more cytopathic effect was recorded as +++.
[0028] After the CPE observation was completed, the MTT method was used to detect the inhibition rate of the drug on ADV7. The specific steps were as follows: 50 μL (5 mg mL MTT) was added to each well. -1 ), incubate for 3-4 hours, remove the supernatant, add an equal volume of DMSO to dissolve the precipitate. Read the corresponding absorbance (OD) at 492nm using an enzyme reader 492 The inhibitory rate of the drug on ADV7 was calculated using the following formula. SPSS11.5 software was used to calculate the half effective concentration of the drug (Concentration for 50% of maximal effect, EC 50 ).
[0029]
[0030] 2.1.3 Therapeutic Index (TI) of Drugs
[0031] TI=CC 50 / EC 50 The higher the therapeutic index, the greater the antiviral potential.
[0032] 3. Experimental results
[0033] Table 1 AT13387 cytotoxicity and anti-ADV7 activity
[0034]
[0035] The results of the compound cytotoxicity and anti-ADV7 activity tests are shown in Table 1. The concentration-dependent effects of the compounds on the survival rate of Hela cells acted with ADV7 are shown in Table 1. Figure 1 It was found that the maximum inhibition rate of AT13387 was about 95% at 12.5 μM.
[0036] The applicant has conducted in-depth research on the anti-ADV7 activity of AT13387 and carried out a test on the inhibitory effect of the compound on the production of ADV7 progeny viruses. The test results are as follows:
[0037] 1. Test content
[0038] The inhibitory effect of the compound on the production of ADV7 progeny virus was detected after ADV7 infected Hela cells.
[0039] 2. Test methods
[0040] Hela cells in logarithmic growth phase were plated in 24-well plates and 100 TCID 50ADV7 infected cells, incubated at 37℃ for 1.5h, removed the virus solution, washed three times with PBS, and added cell maintenance solution containing 6.25μM concentration. After 48h, cells and supernatant culture medium were collected, and lysed by freezing and thawing three times at -20℃ and 37℃, and TCID 50 Methods The ADV7 virus titer was determined.
[0041] 3. Test results
[0042] like Figure 2 As shown, the cell survival rate of Hela cells infected with ADV7 treated with AT13387 was significantly increased compared with the virus control group, indicating that the compound can significantly inhibit the activity of ADV7.
[0043] like Figure 3 As shown, the virus titer of Hela cells treated with the compound was significantly decreased compared with the virus control group, which was decreased by 5.98 log relative to the virus control.
[0044] In summary, AT13387 has a strong inhibitory activity against ADV7, can inhibit Hela cell death caused by ADV7 virus, and has the potential to be prepared into a clinically effective drug against ADV7 infection.
[0045] It should be understood that the above embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.
Claims
1. The application of Onalespib in anti-ADV7 virus drugs is characterized by: The chemical structure of the compound AT13387 having anti-ADV7 activity is shown below:
2. The use of Onalespib as an anti-ADV7 virus drug according to claim 1, characterized in that: Onalespib inhibited ADV7 by approximately 95% at 12.25 μM.
3. The use of Onalespib as an ADV7 virus inhibitor according to claim 1, characterized in that: The application refers to adding pharmaceutically acceptable excipients and carriers to the compound to prepare an anti-ADV7 virus preparation.
4. The use of Onalespib as an ADV7 virus inhibitor according to claim 1, characterized in that: The preparation is any one of granules, tablets, pills, capsules, injections or dispersions.
Citation Information
Patent Citations
Application of 3,5-(E)-diarylmethylene-N-cyclopropyl piperidin-4-one compounds as Hsp90 depressant
CN106083704A
Application of Onalspib compound in preparation of anti-EV71 virus medicine
CN113332286A
Application of Onalspib in preparation of medicine for preventing and / or treating adenovirus infection
CN114767683A
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US20170274077A1
